CSKN Pharma Limited
(previously Esho Pharma Limited)
Unaudited Financial Statements
For the year ended 31 March 2024
Pages for Filing with Registrar
Company Registration No. 12408932 (England and Wales)
CSKN Pharma Limited
(previously Esho Pharma Limited)
Contents
Page
Balance sheet
1
Notes to the financial statements
2 - 5
CSKN Pharma Limited
(previously Esho Pharma Limited)
Balance Sheet
As at 31 March 2024
Page 1
2024
2023
Notes
£
£
£
£
Current assets
Stock
129,371
154,312
Debtors
3
14,135
34,327
Cash at bank and in hand
858
4,220
144,364
192,859
Creditors: amounts falling due within one year
4
(558,431)
(442,122)
Net current liabilities
(414,067)
(249,263)
Capital and reserves
Called up share capital
5
1
1
Profit and loss reserves
(414,068)
(249,264)
Total equity
(414,067)
(249,263)

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and signed by the director and authorised for issue on 4 August 2025
Dr O O Esho
Director
Company Registration No. 12408932
CSKN Pharma Limited
(previously Esho Pharma Limited)
Notes to the Financial Statements
For the year ended 31 March 2024
Page 2
1
Accounting policies
Company information

CSKN Pharma Limited is a private company limited by shares incorporated in England and Wales. The registered office is Charlotte Building, 17 Gresse Street, London, W1T 1QL. On 15 July 2025, the company changed its name from Esho Pharma Limited.

1.1
Accounting convention

These financial statements have been prepared in accordance with Section 1A of FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

The company suffered a net loss in the year of £true164,804 (2023: £249,407) and at the balance sheet date had net liabilities of £414,067 (2023: £249,263). These results reflect a transitional period as the Group undertakes a strategic restructure designed to enhance long-term operational efficiency, streamline service lines, and position the business for sustainable future growth.

 

The restructure is part of a planned, group-wide initiative to align financial resources with evolving commercial objectives. The Group benefits from strong intra-group relationships, with continued financial support available from related entities as needed. As at the balance sheet date, amounts due to related parties total £471,727 (2023: £374,271).

 

At the time of approving the financial statements, the director is confident in the company’s ability to meet its obligations and operate as a going concern, based on current cash flow forecasts, restructuring progress, and continued group support. Accordingly, the financial statements have been prepared on a going concern basis.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

1.4
Stock

Stock are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stock to their present location and condition.

 

Stock held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stock over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

CSKN Pharma Limited
(previously Esho Pharma Limited)
Notes to the Financial Statements (Continued)
For the year ended 31 March 2024
1
Accounting policies
(Continued)
Page 3
1.5
Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks.

1.6
Financial instruments

The company only has basic financial instruments measured at amortised cost.

1.7
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

Changes in the fair value of derivatives that are designated and qualify as fair value hedges are recognised in profit or loss immediately, together with any changes in the fair value of the hedged asset or liability that are attributable to the hedged risk.

1.8
Taxation

The tax expense represents the sum of the tax currently payable.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

1.9
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
-
0
-
0
CSKN Pharma Limited
(previously Esho Pharma Limited)
Notes to the Financial Statements (Continued)
For the year ended 31 March 2024
Page 4
3
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
8,066
14,186
Corporation tax recoverable
888
-
0
Other debtors
4,062
19,719
Prepayments and accrued income
1,119
422
14,135
34,327
4
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
75,586
60,254
Amounts owed to group undertakings
471,727
374,271
Corporation tax
-
0
32
Other creditors
5,618
-
Accruals and deferred income
5,500
7,565
558,431
442,122
5
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and not fully paid
1 Ordinary share of £1 each
1
1
1
1

 

6
Related party transactions

Included in creditors a balance of £453,380 (2023: £362,037) due to CSKN Medical Limited, a company under common control.

 

Included in creditors a balance of £18,347 (2023: £12,234) due from CSKN Franchising Limited, a company under common control.

 

At the balance sheet date £5,500 (2023: £nil) is due to the director.

CSKN Pharma Limited
(previously Esho Pharma Limited)
Notes to the Financial Statements (Continued)
For the year ended 31 March 2024
Page 5
7
Parent company

The parent company is Esho Holdings Limited by virtue of its 100% shareholding in the company.

The ultimate controlling party is Dr O O Esho, the director of the company, by virtue of his 100% shareholding in the immediate parent company; Esho Holdings Limited.

2024-03-312023-04-01falsefalsefalseCCH SoftwareCCH Accounts Production 2025.100No description of principal activityDr O O Esho124089322023-04-012024-03-31124089322024-03-31124089322023-03-3112408932core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3112408932core:CurrentFinancialInstrumentscore:WithinOneYear2023-03-3112408932core:ShareCapital2024-03-3112408932core:ShareCapital2023-03-3112408932core:RetainedEarningsAccumulatedLosses2024-03-3112408932core:RetainedEarningsAccumulatedLosses2023-03-3112408932core:ShareCapitalOrdinaryShareClass12024-03-3112408932core:ShareCapitalOrdinaryShareClass12023-03-3112408932bus:Director12023-04-012024-03-31124089322022-04-012023-03-3112408932core:CurrentFinancialInstruments2024-03-3112408932core:CurrentFinancialInstruments2023-03-3112408932bus:OrdinaryShareClass12023-04-012024-03-3112408932bus:OrdinaryShareClass12024-03-3112408932bus:OrdinaryShareClass12023-03-3112408932bus:PrivateLimitedCompanyLtd2023-04-012024-03-3112408932bus:FRS1022023-04-012024-03-3112408932bus:AuditExempt-NoAccountantsReport2023-04-012024-03-3112408932bus:SmallCompaniesRegimeForAccounts2023-04-012024-03-3112408932bus:FullAccounts2023-04-012024-03-31xbrli:purexbrli:sharesiso4217:GBP